Vepafestinib | RET inhibitor | Probechem Biochemicals

Chemical Structure : Vepafestinib

CAS No.: 2129515-96-2

Vepafestinib (TAS0953, TAS-0953, HM06)

Catalog No.: PC-38426Not For Human Use, Lab Use Only.

Vepafestinib (TAS0953, HM06) is a next-generation RET inhibitor, potently inhibits recombinant WT RET kinase with IC50 of 0.33 nM, targets RET wild-type (WT) kinase and RET solvent front mutants (RETL730, RETV804 and RETG810).

Packing	Price	Stock
5 mg	$258	In stock
10 mg	$388	In stock
25 mg	$598	In stock
100 mg		Get quote
200 mg		Get quote
1 g		Get quote

Get Quotation Now

* Please select Quantity before adding items.

or Bulk Inquiry

Bulk size, bulk discount!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

Biological Activity

Vepafestinib (TAS0953, HM06) is a next-generation RET inhibitor, potently inhibits recombinant WT RET kinase with IC50 of 0.33 nM, targets RET wild-type (WT) kinase and RET solvent front mutants (RETL730, RETV804 and RETG810).

Vepafestinib (TAS0953, HM06) displays excellent kinase selectivity against a panel of 255 recombinant kinases.

Vepafestinib (TAS0953, HM06) potently inhibits growth of Ba/F3 cells expressing KIF5B–RETWT or KIF5B–RET mutants (V804M, V804L, G810R, G810S, G810C), but not selpercatinib and pralsetinib.

Vepafestinib (TAS0953, HM06) suppresses phosphorylation of RETG810R, RETG810S and RETG810C with near-complete inhibition at 100 nM in Ba/F3 KIF5B–RETWT cells, but not selpercatinib and pralsetinib.

Vepafestinib (TAS0953, HM06) inhibits transmission of signals and blocks growth of cells with RET alterations, effectively inhibits cell growth of HBECp53-RET (CCDC6-RET fusion; IC50 = 60 nM), with little effect on the isogenic control HBECp53-EV cells.

Vepafestinib (TAS0953, HM06) modulates expression of cell cycle and apoptosis markers.

Vepafestinib (TAS0953, HM06) treatment (50 mg per kg BID and 100 mg per kg, once daily (QD)) caused significant reductions in ECLC5B xenograft tumor growth, shows anti-tumor activity against KIF5B–RETG810R-driven allograft tumors.

Vepafestinib (TAS0953, HM06) is more effective than selpercatinib at penetrating the brain and blocking intracranial tumor growth.

Physicochemical Properties

M.Wt	474.565
Formula	C26H30N6O3
Appearance	Solid
CAS No.
Storage	Solide Powder -20°C 12 Months; 4°C 6 Months	In Solvent -80°C 6 Months; -20°C 6 Months
Shipping
Solubility	10 mM in DMSO
Chemical Name/SMILES	4-amino-N-(4-(methoxymethyl)phenyl)-7-(1-methylcyclopropyl)-6-(3-morpholinoprop-1-yn-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide

References

1. Patent WO2017146116 A1.

Select Your Country or Region

Vepafestinib (TAS0953, TAS-0953, HM06)

Biological Activity

Physicochemical Properties

References

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

Get Quote

* Indicates a Required FieldYour information is safe with us.